Related Experiment Video
Updated: Aug 11, 2026

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
Published on: September 11, 2019
[Diabetic ketoacidosis in an HIV-infected patient undergoing antiretroviral therapy]
Malene Rahbek Holm1, Birgitte Rønde Hansen, Michael E Røder
1H:S Hvidovre Hospital, Endokrinologisk Klinik, Infektionsmedicinsk Afdeling. malenerahbekholm@dadlnet.dk
Following the introduction of highly active antiretroviral therapy (HAART), a number of metabolic and morphologic alterations, known as HIV-associated lipodystrophy syndrome (HALS), have been increasingly common in HIV-infected patients being treated with this therapy. The use of protease inhibitors (PI), in particular, has been associated with insulin resistance and hyperglycaemia, but only infrequently with diabetic ketoacidosis. We report a case of diabetic ketoacidosis in an HIV-infected woman after 1(1/2) years of a PI-containing regimen, demonstrating reduced beta cell function and insulin resistance.
Following the introduction of highly active antiretroviral therapy (HAART), a number of metabolic and morphologic alterations, known as HIV-associated lipodystrophy syndrome (HALS), have been increasingly common in HIV-infected patients being treated with this therapy. The use of protease inhibitors (PI), in particular, has been associated with insulin resistance and hyperglycaemia, but only infrequently with diabetic ketoacidosis. We report a case of diabetic ketoacidosis in an HIV-infected woman after 1(1/2) years of a PI-containing regimen, demonstrating reduced beta cell function and insulin resistance.
Related Concept Videos
Diabetic Ketoacidosis l: Introduction
Diabetic Ketoacidosis ll: Pathophysiology
Retrovirus Life Cycles
Cryptococcal Meningitis
Complications of Diabetes Mellitus
Type I Diabetes III: Clinical Manifestations

